SAB Biotherapeutics Warrant
SABSW
12 hedge funds and large institutions have $43.8K invested in SAB Biotherapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
15% more capital invested
Capital invested by funds: $38.1K → $43.8K (+$5.75K)
0.18% less ownership
Funds ownership: 2.41% → 2.23% (-0.18%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$333 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
| 3 |
CS
Clear Street
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.12K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$872 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1 |
SABSW Hedge Fund Activity: Q1 2024 in Review
12 of the 6,960 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2024, worth a combined $43.8K — up 15% from $38.1K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SABSW positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $333. The largest seller was Shaolin Capital Management, cutting an estimated $2.12K.
- 12 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2024, up from 10 in Q4 2023.
- Funds reported $43.8K of SAB Biotherapeutics Warrant stock for Q1 2024, up 15% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics Warrant positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q1 2024 was Susquehanna International Group, an estimated $333 added.
- The largest SAB Biotherapeutics Warrant seller in Q1 2024 was Shaolin Capital Management, an estimated $2.12K sold.
Based on aggregated 13F filings for Q1 2024.